文献速递甲状腺疾病

未接受放射性碘治疗的ATA低危儿童甲状腺癌患者的结局

Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本研究回顾2010至2020年接受全甲状腺切除术的19岁以下分化型甲状腺癌患者,分析美国甲状腺协会(ATA)低危患者接受与未接受放射性碘治疗(RAIT)的缓解率。95例中50例接受RAIT、45例未接受,1年缓解率分别为70%与69%,无显著差异;长期随访缓解率分别升至82%与76%。作者结论认为对ATA低危儿童患者省略RAIT不损害缓解率。

要点

  • ATA低危儿童分化型甲状腺癌患者接受与未接受RAIT的1年缓解率无显著差异(70% vs 69%)。
  • 2015年前82%患者接受RAIT,2015年后降至33%(P < .01)。
  • 未发现RAIT、N1a病变或2015年后手术等持续或不确定疾病状态的危险因素。

核心结论

  • 对ATA低危儿童分化型甲状腺癌患者省略RAIT可避免辐射暴露,且对缓解率无负面影响。
  • 初始治疗后1年的动态危险分层是评估省略RAIT影响的合适时间点。

研究设计与样本

  • 回顾性分析2010至2020年诊断为分化型甲状腺癌并接受全甲状腺切除术的19岁以下患者的病历记录。
  • 采用多变量逻辑回归评估影响RAIT实施和缓解率的因素。
  • 共分析95例ATA低危分化型甲状腺癌患者,其中50例(53%)接受RAIT,45例(47%)未接受RAIT。

主要发现

  • 2015年前82%的患者接受RAIT,而2015年后为33%(P < .01)。
  • 接受与未接受RAIT患者的1年缓解率分别为70%(35/50)与69%(31/45),无显著差异。
  • 随着监测时间延长,接受与未接受RAIT患者的缓解率分别增至82%与76%。
  • 接受与未接受RAIT队列的中位随访时间分别为5.8年(IQR 4.3-7.9,范围0.9-10.9)与3.6年(IQR 2.7-6.6,范围0.9-9.3)。
  • 未发现持续或不确定疾病状态的危险因素,包括RAIT实施、N1a病变和2015年后手术。

关键数值与推荐

  • 美国甲状腺协会(ATA)儿童指南推荐局限于甲状腺的分化型甲状腺癌患者不接受放射性碘治疗(RAIT)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The American Thyroid Association (ATA) Pediatric Guidelines recommend patients not receive radioactive iodine therapy (RAIT) for differentiated thyroid cancer (DTC) confined to the thyroid. Since publication, there is ongoing concern whether withholding RAIT will result in a lower rate of remission. OBJECTIVE: This study explores whether ATA low-risk patients treated with and without RAIT achieved similar remission rates. METHODS: Medical records of patients <19 years old diagnosed with DTC and treated with total thyroidectomy between 2010 and 2020 were reviewed. Multivariate logistic regression was performed to evaluate factors influencing RAIT administration and remission rate. RESULTS: Ninety-five patients with ATA low-risk DTC were analyzed: 53% (50/95) and 47% (45/95) were treated with and without RAIT, respectively. RAIT was used to treat 82% of patients before 2015 compared with 33% of patients after 2015 (P < .01). No significant difference in 1-year remission rate was found between patients treated with and without RAIT, 70% (35/50) vs 69% (31/45), respectively. With longer surveillance, remission rates increased to 82% and 76% for patients treated with and without RAIT, respectively. Median follow-up was 5.8 years (IQR 4.3-7.9, range 0.9-10.9) and 3.6 years (IQR 2.7-6.6; range 0.9-9.3) for both cohorts. No risk factors for persistent or indeterminate disease status were found, including RAIT administration, N1a disease, and surgery after 2015. CONCLUSION: Withholding RAIT for pediatric patients with ATA low-risk DTC avoids exposure to radiation and does not have a negative impact on remission rates. Dynamic risk stratification at 1-year after initial treatment is a suitable time point to assess the impact of withholding RAIT for these patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bojarsky M, Baran JA, Halada S, et al. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy. J Clin Endocrinol Metab. 2023. PMID: 37265226. doi:10.1210/clinem/dgad322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。